Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

161

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors
NSCLC
Bladder Cancer
HNSCC
Renal Cancer
Melanoma
Anal Cancer
Colorectal Cancer
Cholangiocarcinoma
Gastric Cancer
Hepatocellular Carcinoma
Merkel Cell Carcinoma
Cervical Cancer

Interventions

DRUG: Continue PD-1/PD-L1 Inhibitors treatment
OTHER: Discontinue PD-1/PD-L1-1 inhibitor

Sponsor

Dan Zandberg